(EGX:LCSW) Lecico Egypt (S.A.E.) produces and sells sanitary ware products and various tiles in Egypt and Lebanon. The company’s products include bathroom suites, toilets, washbasins, and bidets and urinals; and squatting pan, shower trays, kitchen sink, and taps, as well as other complementary products.The company exports its products. It sells its products under the Lecico brand.Lecico Egypt (S.A.E.) was incorporated in 1975 and is based in Alexandria, Egypt
Mid-Term Target Price (Fair Value Avg): ~85 EGP, implying ~237% potential upside from current levels.
• Technically Weak in Short-Term: Below EMA 200 and entering the Wave C correction suggests consolidation or dip toward the 21–25 EGP range before an upside move.
Technical Overview
• Current Price (April 3, 2025): 25.2 EGP/share
• 52-Week Range: 15.00 – 34.84 EGP/share
• Book Value per Share is 46.68 EGP
• Below EMA 200: Bearish sign; technically under long-term resistance
• Rate of Change (ROC): 24.6 EGP/share
• Gann Analysis TP: ~34.5 EGP in May 2025 (based on (15.02)2+2(15.02)^2 + 2(15.02)2+2)
• Elliott Wave Analysis: In Wave C (correction), target zone: 21–25 EGP/share (current price near upper bound)
Financial Highlights – FY 2024
• Revenue: EGP 6.64 billion (↑ 37% YoY)
• Net Profit: EGP 890.3 million (↑ 99% YoY)
• EPS: 11.13 EGP
• Sanitary Ware: 64.8% of revenue, 77.9% export-driven
• EBIT: EGP 1,151 million (↑ 22%)
• Margins:
o Gross: 28.22%
o Operating (EBIT): 17.32%
o Profit: 13.40%
o EBITDA: 19.47%
Interpretation & Conclusion
• Fundamentally Undervalued: With a P/E of 2.26× and P/B of 0.54×,
Lecico appears significantly undervalued given its strong profitability and book value.
Investment Strategy
If you’re a long-term investor:
• Accumulate in the 21–25 EGP correction zone.
• Monitor EMA 200 breakout and ROC reversal for momentum entry.
Mid-Term Upside Targets
• TP1: 34.5 EGP (Gann target)
• TP2: 58.8 EGP (DCF Value )
• TP3: 65.6 EGP (CHF estimate) refer to Cairo Financial Holding company
• TP4: 85.0–105.6 EGP (Sector-based fair value) refer to Ostoul Securities Brokerage Bond Trading Company
Mid-Term Target Price (Fair Value Avg): ~85 EGP, implying ~237% potential upside from current levels.
• Technically Weak in Short-Term: Below EMA 200 and entering the Wave C correction suggests consolidation or dip toward the 21–25 EGP range before an upside move.
Technical Overview
• Current Price (April 3, 2025): 25.2 EGP/share
• 52-Week Range: 15.00 – 34.84 EGP/share
• Book Value per Share is 46.68 EGP
• Below EMA 200: Bearish sign; technically under long-term resistance
• Rate of Change (ROC): 24.6 EGP/share
• Gann Analysis TP: ~34.5 EGP in May 2025 (based on (15.02)2+2(15.02)^2 + 2(15.02)2+2)
• Elliott Wave Analysis: In Wave C (correction), target zone: 21–25 EGP/share (current price near upper bound)
Financial Highlights – FY 2024
• Revenue: EGP 6.64 billion (↑ 37% YoY)
• Net Profit: EGP 890.3 million (↑ 99% YoY)
• EPS: 11.13 EGP
• Sanitary Ware: 64.8% of revenue, 77.9% export-driven
• EBIT: EGP 1,151 million (↑ 22%)
• Margins:
o Gross: 28.22%
o Operating (EBIT): 17.32%
o Profit: 13.40%
o EBITDA: 19.47%
Interpretation & Conclusion
• Fundamentally Undervalued: With a P/E of 2.26× and P/B of 0.54×,
Lecico appears significantly undervalued given its strong profitability and book value.
Investment Strategy
If you’re a long-term investor:
• Accumulate in the 21–25 EGP correction zone.
• Monitor EMA 200 breakout and ROC reversal for momentum entry.
Mid-Term Upside Targets
• TP1: 34.5 EGP (Gann target)
• TP2: 58.8 EGP (DCF Value )
• TP3: 65.6 EGP (CHF estimate) refer to Cairo Financial Holding company
• TP4: 85.0–105.6 EGP (Sector-based fair value) refer to Ostoul Securities Brokerage Bond Trading Company
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.